New York State Common Retirement Fund Reduces Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

New York State Common Retirement Fund decreased its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 9.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 23,382 shares of the company's stock after selling 2,481 shares during the period. New York State Common Retirement Fund owned about 0.08% of Krystal Biotech worth $3,663,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Creative Planning increased its stake in shares of Krystal Biotech by 64.9% during the third quarter. Creative Planning now owns 5,744 shares of the company's stock valued at $1,046,000 after purchasing an additional 2,260 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Krystal Biotech by 21.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,039 shares of the company's stock worth $184,000 after purchasing an additional 186 shares during the last quarter. New York State Teachers Retirement System raised its position in Krystal Biotech by 6.6% in the 3rd quarter. New York State Teachers Retirement System now owns 15,879 shares of the company's stock worth $2,890,000 after buying an additional 979 shares during the last quarter. First Trust Direct Indexing L.P. purchased a new stake in shares of Krystal Biotech during the 3rd quarter valued at about $252,000. Finally, Janney Montgomery Scott LLC grew its position in Krystal Biotech by 17.1% in the 3rd quarter. Janney Montgomery Scott LLC now owns 37,047 shares of the company's stock worth $6,744,000 after purchasing an additional 5,415 shares during the period. Hedge funds and other institutional investors own 86.29% of the company's stock.

Remove Ads

Krystal Biotech Trading Up 2.1 %

Shares of NASDAQ KRYS traded up $3.69 during midday trading on Tuesday, reaching $175.52. The company had a trading volume of 161,507 shares, compared to its average volume of 262,461. The business's 50-day simple moving average is $159.63 and its 200 day simple moving average is $174.93. The stock has a market cap of $5.06 billion, a P/E ratio of 58.56 and a beta of 0.87. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. The company had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm's quarterly revenue was up 116.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.30 earnings per share. Analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on KRYS. Chardan Capital upped their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a report on Thursday, February 20th. HC Wainwright reissued a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a report on Friday. Citigroup boosted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Krystal Biotech presently has a consensus rating of "Buy" and a consensus price target of $215.83.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by company insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).